Glenmark's RYALTRIS brings dual-action therapy to Brazil, expanding treatment options for patients with moderate to severe allergic rhinitis symptoms.
Trial results today are reshaping pharma fortunes, with clinical successes boosting confidence while failures trigger sharp market reactions.
Natco Pharma plans a ?1,300 crore rights issue as it builds funding capacity for M&A. The move adds to its QIP plan and ?3,500 crore cash reserves for strategic acquisitions.
China’s Wegovy approval for MASH strengthens Novo Nordisk’s global position, extending the GLP-1 drug’s reach from weight management into liver disease.
AstraZeneca’s tozorakimab cuts COPD flare-ups by 29-34 percent, offering broad benefits across patients regardless of smoking status or eosinophil levels.
Pharma Today tracks how capital, investment and biosimilars shape new moves across India’s drug industry, with Sun Pharma, ChrysCapital and Lupin advancing distinct growth priorities.
The government panel backs continued home drug delivery, prioritizing medicine access for vulnerable patients while calling for tighter online sales enforcement.
BMS’s third CAR-T bet pays off as arlo-cel shows meaningful response gains in heavily pretreated multiple myeloma patients.
Tylenol exposure in pregnancy draws fresh scrutiny as the latest evidence links prenatal exposure to reproductive changes in daughters.
Lung disease pipeline advances as a cancer combo and PH-ILD drug deliver strong survival, pressure, and functional gains.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")